Cypress Capital Management LLC Buys 171,068 Shares of Pfizer Inc. (NYSE:PFE)

Cypress Capital Management LLC lifted its stake in Pfizer Inc. (NYSE:PFE) by 764.4% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 193,447 shares of the biopharmaceutical company’s stock after buying an additional 171,068 shares during the quarter. Cypress Capital Management LLC’s holdings in Pfizer were worth $7,009,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also added to or reduced their stakes in PFE. North American Management Corp grew its holdings in Pfizer by 4.0% during the 1st quarter. North American Management Corp now owns 186,886 shares of the biopharmaceutical company’s stock valued at $6,771,000 after buying an additional 7,122 shares in the last quarter. Jones Financial Companies Lllp lifted its stake in shares of Pfizer by 2.0% in the 1st quarter. Jones Financial Companies Lllp now owns 358,298 shares of the biopharmaceutical company’s stock valued at $12,981,000 after purchasing an additional 7,005 shares during the last quarter. Wellington Shields Capital Management LLC lifted its stake in shares of Pfizer by 7.6% in the 4th quarter. Wellington Shields Capital Management LLC now owns 104,766 shares of the biopharmaceutical company’s stock valued at $3,856,000 after purchasing an additional 7,405 shares during the last quarter. Kanawha Capital Management LLC lifted its stake in shares of Pfizer by 2.5% in the 1st quarter. Kanawha Capital Management LLC now owns 233,336 shares of the biopharmaceutical company’s stock valued at $8,454,000 after purchasing an additional 5,682 shares during the last quarter. Finally, Roosevelt Investment Group LLC lifted its stake in shares of Pfizer by 11.8% in the 1st quarter. Roosevelt Investment Group LLC now owns 91,124 shares of the biopharmaceutical company’s stock valued at $3,301,000 after purchasing an additional 9,625 shares during the last quarter. Hedge funds and other institutional investors own 64.22% of the company’s stock.

In other news, SVP Jennifer B. Damico sold 2,500 shares of Pfizer stock in a transaction on Wednesday, May 5th. The stock was sold at an average price of $40.82, for a total value of $102,050.00. Following the transaction, the senior vice president now directly owns 13,748 shares in the company, valued at approximately $561,193.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 0.05% of the company’s stock.

Shares of NYSE:PFE traded down $0.67 on Friday, reaching $40.01. The company had a trading volume of 459,979 shares, compared to its average volume of 30,701,137. Pfizer Inc. has a 52-week low of $31.61 and a 52-week high of $43.08. The business has a 50 day moving average of $38.76. The firm has a market capitalization of $223.96 billion, a price-to-earnings ratio of 20.76, a PEG ratio of 1.42 and a beta of 0.74. The company has a quick ratio of 1.16, a current ratio of 1.48 and a debt-to-equity ratio of 0.51.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, May 4th. The biopharmaceutical company reported $0.93 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.78 by $0.15. Pfizer had a return on equity of 24.55% and a net margin of 22.09%. The business had revenue of $14.58 billion for the quarter, compared to the consensus estimate of $13.41 billion. During the same period last year, the business posted $0.80 EPS. The business’s revenue was up 44.6% compared to the same quarter last year. As a group, equities analysts expect that Pfizer Inc. will post 3.69 EPS for the current year.

The business also recently declared a quarterly dividend, which was paid on Friday, June 4th. Stockholders of record on Friday, May 7th were issued a $0.39 dividend. The ex-dividend date was Thursday, May 6th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 3.90%. Pfizer’s dividend payout ratio is presently 70.27%.

Several research firms have recently issued reports on PFE. Barclays raised their price objective on Pfizer from $37.00 to $40.00 and gave the company an “equal weight” rating in a research note on Wednesday, May 5th. Royal Bank of Canada began coverage on Pfizer in a research note on Wednesday, April 7th. They set a “sector perform” rating and a $42.00 price target for the company. Mizuho reissued a “neutral” rating and set a $42.00 price target on shares of Pfizer in a research note on Wednesday, May 12th. TheStreet raised Pfizer from a “c+” rating to a “b-” rating in a research note on Monday, May 3rd. Finally, The Goldman Sachs Group set a $45.00 price target on Pfizer and gave the stock a “neutral” rating in a research note on Monday, May 24th. Twelve research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $39.73.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands.

Recommended Story: Technical Indicators – What is a Golden Cross?

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.